INTRODUCTION

STATEMENT OF PROBLEM
Nonhealing or slow-healing wounds are a major health problem, not only for those persons who suffer from them but also for those who treat them and those who are responsible for the cost of their treatment. Although autologous cellular grafts and reconstructed skin are beneficial in certain instances, such costly specialized and time-consuming procedures are not applicable to all clinical situations. The enhancement of wound healing using pharmaceutical agents can be of great benefit in surgery, burns and dermal ulcers, ophthalmology, and orthopedics, especially for the Navy
The objective of this research is the development of therapeutic agents that can enhance wound healing by stimulating the mitogenesis and chemotaxis of appropriate cells. Plateletderived growth factor (PDGF) has both these properties and it has been reported that both these properties are located in different domains. Our aim is to identify these active domains. Specifically, we proposed to * Synthesize a series of peptides of various lengths from the A and B chain sequences of human PDGF. Proteolytic cleavage sites and computer-graphic sequence analysis were considered in selecting the sequence and length of the peptide to be synthesized.
* Test the binding of the peptides to mouse 3T3 cells by radioreceptor assay. These cells have receptors for both PDGF A and B chains.
* Test peptides for mitogenic and chemotactic activity.
* Test potent peptides for wound healing in a mouse model.
" Synthesize smaller fragments of active peptides to determine the minimum sequence required for activity.
BACKGROUND
PDGF is a 32-KD protein heterodimer composed of A and B polypeptide chains linked by disulfide bonds. It is stored in the a-granules of platelets and released when platelets are activated by blood clotting and contact with sites of injury . It stimulates specific target cells by binding to cell-surface receptors, thereby mediating a cascade of events that lead to DNA synthesis and cell proliferation. PDGF is a strong mitogen for fibroblasts, smooth muscle cells, and glial cells (Ross and Vogel, 1978; Stiles, 1983) . In addition, it is a potent chemotactic factor for neutrophils, monocytes, fibroblasts, and smoothmuscle cells (Deuel etal., 1982; Grotendorst etal., 1981 Grotendorst etal., , 1982 Senior et al., 1983; Seppa et al., 1982) . Thus, PDGF plays an important role in the migration of inflammatory and connectivetissue cells to sites of inflammation and injury and in the repair or restructuring of injured tissues.
SCIENTIFIC PROGRESS DURING THE PAST YEAR
PEPTIDE SYNTHESIS
During the past year, we synthesized and purified 13 peptides, 4 from PDGF A chain and 10 from PDGF B chain. The sequences of these peptides are shown in Tables 1 and 2 . PDGF A (12-28) and (101-125), PDGF B (22-36), (43-57), and (101-117) represent amphipathic helices, in which one face of the helix is occupied preferentially by lipophilic side chains; hydrophilic residues are located at the opposite face. Such a structure provides a stable conformation to the peptide by reacting with membrane through the hydrophobic side of the helix. PDGF B (86-114) was synthesized because this region was reported to show binding affinity (Vogel and Hoppe, 1989) . The rest of the peptides were selected on the basis of human leukocyte elastase and cathepsin G cleavage sites. All the peptides were acetylated at the amino terminus and amidated at the carboxy terminus except PDGF B (86-119), to exclude the unnatural free amino and carboxyl groups. Peptides with more than one cysteine in their sequence were cyclized. 
EVALUATION OF PEPTIDES
All the peptides mentioned above were tested for cell binding and mitogenesis, and seven were tested for chemotaxis.
EXPERIMENTAL METHODS
PEPTIDE SYNTHESIS
The peptides were synthesized by the solid-phase technique on a Beckman 990C Automated Peptide Synthesizer, starting with commercially available t-BOC amino acid benzhydrylamine (BHA) or methylbenzhydrylamine (MBHA) resin and t-BOC-protected amino acids with the following side-chain protecting groups: O-benzyl esters for aspartic acid and glutamic acid, O-benzyl ethers for serine and threonine, tosyl for arginine and histidine, pmethoxybenzyl for cysteine, ortho-chlorobenzyloxycarbonyl for lysine, and 2,6-dichlorobenzyl for tyrosine. All couplings were performed using a 3-mol excess of t-BOC amino acid and dicyclohexyl-carbodiimide (DCC) over the number of millequivalents of amino acid on the resin. Every coupling was repeated, and the repeat coupling was performed as hydroxybenzotriazole (HOBT) active ester. In the case of asparagine and glutamine, both couplings were performed as HOBT active ester. For BOC deprotection, 40% TFA-CH 2 C12 containing 10% anisole and 0.1% indole was used. Details of the synthetic cycle are given in Table 3 . 
ACETYLATION
After the last coupling, the BOC group was removed and the peptide resin was neutralized with 7% diisopropyl ethylamine (DIEA) and washed with CH 2 C1 2 (4x) and DMF. A solution of 500 mg of HOBT per gram of resin in DMF was added followed by 2 mL of acetic anhydride. The mixture was stirred for I hr, then the peptide resin was washed thoroughly with DMF, CH 2 C1 2 , iPrOH, and CH2C2 and dried.
CLEAVAGE OF THE PEPTIDE FROM THE RESIN AND PURIFICATION
Peptides were cleaved from the resin by using anhydrous HF in HF-Reaction Apparatus
Type II (Peninsula Labs). HF (10 mL/g peptide resin) was distilled into the reaction vessel containing peptide resin plus anisole (1 mL/g resin). If the peptide contained cysteine or methionine, then dimethylsulfide (0.5 mL/g resin) was also added. The mixture was stirred at 4°C for 1 hr. HF was then distilled off completely under vacuum, first at 4'C and then at room temperature. The peptides were separated from the various organic side products by extraction with ether. Peptides were isolated by extraction with 50% acetic acid, then diluted and lyophilized. The crude peptides were purified on high-pressure liquid chromatography (HPLC) using a 20-mm x 50-cm column packed with Vydac 15-to 20-. C 1 8.
The final peptides were obtained in 20% to 40% yield in >95% purity by HPLC (Figures 1 through 10) . Amino acid analysis of all peptides agreed within ±10% of the theoretical value (Table 4) .
CYCLIZATION OF PEPTIDES
The cyclic disulfides were formed by air oxidation of a dilute solution of purified peptide in water. The solution pH was adjusted to 8 by adding 50% concentrated NH 4 OH in water, and the solution was then shaken slowly on an orbital shaker for 7 days. An Ellman test was then performed to confirm the completion of the disulfide bond formation. The solution was then lyophilized. 
CELL BINDING ASSAY (COMPETITION
To start the assay, we removed the binding buffer and added 0.25 mL of various concentrations of competitor (PDGF or peptides) to triplicate wells. 125 1-PDGF (5 ng) was added to each well in a volume of 0.25 mL, and binding was conducted typically for 2 hr at 4 0 C. The binding medium was aspirated, and the monolayers were washed 4x with I mL cold binding buffer at 4*C to remove the unbound radioactivity. The cells were solubilized in 0.5 mL of 1 N NaGI-, and a portion of the lystate (0.4 mL) was transferred to tubes. The bound 125 1-PDGF was quantitated by using a gamma counter.
MITOGENESIS ASSAY
Balb/c 3T3 cells were set up at 20,000 cells per well in flat-bottom 96-well plates on day 0. Cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% (v/v) fetal calf serum (FCS). On day 3, the medium was removed and the monolayers were washed once with DMEMo. Cells were incubated in DMEMo for 48 hr at 37'C. PDGF or peptides were added in DMEMo, and ( 3 H)-thymidine ( 3 H-TdR) was added (final concentration, 1 gtCi/mL).
The cells were incubated with ( 3 H-TdR) for 24 hr, then washed with PBS, trypsinized, and collected with an automated cell harvester onto glass fiber filter paper with 5% (w/v) trichloroacetic acid (TCA). The filters were dried, transferred to counting vials, and counted in a liquid scintillation counter. ( 3 H-TdR) incorporation was quantitated in 6 replicate wells.
CHEMOTAXIS ASSAY
The chemotactic response of Balb/c 3T3 cells to PDGF and peptides was assayed by using a modified Boyden chamber. Chemotaxis was quantitated by using a spectrophotometric assay (Grotendorst, 1987) . Chambers were assembled by using polyvinylpyrrolidone-free polycarbonate filters (Nucleopore Corp.). The filters (8-.m-diameter pores) were prewetted in DMEMo containing 0.5% BSA. The lower wells contained 0.2 mL of various concentrations of PDGF or peptides in DMEMo + 0.5% BSA. The upper wells contained 100,000 3T3 cells in 0.2 mL. The assembled chambers were typically incubated for 16 hr at 37'C in 10% C02. After overnight incubation, the filters were removed from the chamber, fixed in methanol, and stained with Wright-Giemsa stain solution (Polysciences, Inc.). The stained filters were placed on glass microscope slides, and the ipper surface cells were carefully removed by scraping with a cotton swab. Care was taken at this step to remove all cellular debris that contained stained material.
After a small amount of water was added to each filter, the filters were removed from the slides, blotted on absorbant paper, and placed in 12-x 75-cm tubes containing 0.5 mL of 0.1 N HCI.
The tube was vortexed, and 0.2 mL was transferred to a 96-well plate for reading in a plate reader. The amount of stain measured at 650 nm for each condition was evaluated in replicates of four filters.
RESULTS AND DISCUSSION
BINDING OF PEPTIDES TO 3T3 FIBROBLASTS
During the year, we tested 13 peptides for cell binding; 3T3 fibroblasts which have receptors for both PDGF A and B chains, were used. Radiolabeled 125 1-PDGF BB was allowed to bind separately to 3T3 cells in the presence of increasing concentrations of unlabeled peptides to determine whether binding is mediated through the PDGF receptors or through some independent moiety. The results are shown in Table 5 These data suggest that both PDGF BB and the peptides bound to a common site. Moreover, the greater concentrations of peptides required to displace PDGF indicate that PDGF binds to 3T3 cells with greater affinity than do the peptides. The IC 5 0 of PDGF BB is 4 pg (Figure 14) . The inhibitory activities of peptides against PDGF AA and AB need to be tested. 
EFFECT OF PEPTIDES ON DNA SYNTHESIS STIMULATED BY SERUM
Varying concentrations of each peptide were diluted in medium without serum and incubated with the cells to determine whether the peptides could modulate the level of DNA synthesis stimulated by serum. None of the peptides tested so far had any effect on DNA synthesis (Table 6) . Recently, we investigated the effect of different serum concentrations in this assay. Results will be reported in our next quarterly report. Table 6 THYMIDINE INCORPORATION AT PEPTIDE CONCENTRATION (cpm/well)
Peptilde
Control (media) 1000 Ug/mL 500 ug/mL 250 ug/mL 
PLANS FOR NEXT YEAR
We plan to synthesize the remaining peptides from Tables 3 through 6, pp.18 and 19; and Tables 9 and 10, p. 2 3 of the original proposal. These peptides will be tested for cell binding, mitogenesis, and chemotaxis. Depending on the data obtained from the biological assays, we will initialize the in vivo wound-healing assay.
